Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion
Authors
Keywords
Autophagic cell death, MTT assay, Renal cell carcinoma, MAPK signaling cascades, Protein extraction, Cell viability testing, Tubulins, Signal inhibition
Journal
PLoS One
Volume 13, Issue 7, Pages e0200878
Publisher
Public Library of Science (PLoS)
Online
2018-07-27
DOI
10.1371/journal.pone.0200878
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways
- (2018) Laura Rosenberg et al. CARCINOGENESIS
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
- (2016) Daniel J Klionsky et al. Autophagy
- Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma
- (2016) Xiangyu Liu et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- The role and mechanism of autophagy in sorafenib targeted cancer therapy
- (2016) Yi Heqing et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Modulation of Autophagy by Sorafenib: Effects on Treatment Response
- (2016) Nestor Prieto-Domínguez et al. Frontiers in Pharmacology
- Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells
- (2015) A Grimaldi et al. CANCER BIOLOGY & THERAPY
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Sorafenib: 10 years after the first pivotal trial
- (2015) Gennaro Gadaleta-Caldarola et al. Future Oncology
- Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation
- (2015) Fariba Fouladi et al. LEUKEMIA & LYMPHOMA
- Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo
- (2015) Hiromoto Tei et al. Human Cell
- Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance
- (2015) Jesús García-Cano et al. Oncotarget
- Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner
- (2015) Irina Kiprianova et al. NEOPLASIA
- ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma
- (2015) Laura Arias-González et al. NEOPLASIA
- ERKs in Cancer: Friends or Foes?
- (2014) Xavier Deschênes-Simard et al. CANCER RESEARCH
- The Four Faces of Autophagy: Implications for Cancer Therapy
- (2014) D. A. Gewirtz CANCER RESEARCH
- Prospects for MEK inhibitors for treating cancer
- (2014) Juan Martin-Liberal et al. Expert Opinion On Drug Safety
- Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
- (2014) B. Zhai et al. MOLECULAR CANCER THERAPEUTICS
- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
- (2014) Ramona Rudalska et al. NATURE MEDICINE
- Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries
- (2014) Camillo Porta et al. Cancer Medicine
- Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation
- (2013) Iori Sakai et al. BJU INTERNATIONAL
- Novel Targeting of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin in Renal Cell Carcinoma
- (2013) Daniel Cho CANCER JOURNAL
- ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition
- (2013) J. M. Buonato et al. CANCER RESEARCH
- E1a promotes c-Myc-dependent replicative stress
- (2013) María Llanos Valero et al. CELL CYCLE
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Sorafenib induces autophagy and suppresses activation of human macrophage
- (2013) Jiunn-Chang Lin et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Stimulatory effects of sorafenib on human non-small cell lung cancer cells in vitro by regulating MAPK/ERK activation
- (2013) YA-NIAN ZHANG et al. Molecular Medicine Reports
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells
- (2013) W-T Tai et al. Cell Death & Disease
- Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model
- (2012) P. Kharaziha et al. CANCER RESEARCH
- Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma
- (2012) S. Xargay-Torrent et al. CLINICAL CANCER RESEARCH
- RAS/RAF/MEK Inhibitors in Oncology
- (2012) M. Broggini CURRENT MEDICINAL CHEMISTRY
- Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
- (2012) Su Jung Oh et al. ENDOCRINE-RELATED CANCER
- Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib
- (2012) Carlo Spirli et al. HEPATOLOGY
- Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma
- (2012) JOHN SHYI PENG YUEN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines
- (2012) Annamaria Piscazzi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The VHL/HIF axis in clear cell renal carcinoma
- (2012) Chuan Shen et al. SEMINARS IN CANCER BIOLOGY
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
- (2012) Dalia Ercan et al. Cancer Discovery
- Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
- (2011) Ying-Hong Shi et al. Autophagy
- Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
- (2011) J S P Yuen et al. BRITISH JOURNAL OF CANCER
- eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206
- (2011) Y. Cheng et al. CANCER RESEARCH
- BRAF as therapeutic target in melanoma
- (2010) Claudia Wellbrock et al. BIOCHEMICAL PHARMACOLOGY
- Pathological roles of MAPK signaling pathways in human diseases
- (2010) Eun Kyung Kim et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma
- (2010) Sharyn I. Katz et al. CANCER BIOLOGY & THERAPY
- Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway
- (2010) Xinchang Lu et al. JOURNAL OF SURGICAL ONCOLOGY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
- (2009) Clara I. Aceves-Luquero et al. PLoS One
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now